We believe that any intensive reading into the data at this stage may be premature,
It's exciting and the potential is enormous, but the challenges and the risks are formidable.
This news is driving investor interest in the area. My caution is that it's still emerging and it's hard to tell who is going to be the winners. I don't like people buying on the hype.
The Phase III results to date are not encouraging.
There's a perceived halo effect, which is negative, that we don't agree with. Each of the cancer vaccine companies should be viewed as different companies.
